声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。2025年以来,有多款重磅新药研发被终止。其中,强生在一周内放弃了两款新药研发项目。3月10日,Genmab宣布强生决定不再行使HexaBody-CD38(GEN3014)的全球开发和商业化选择权。消息出来后,Genmab股价下跌7.8%。来源:企业官网...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.